Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Yoshihiro Miyasaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4344-4448; OpenAlex author ID A5084948765. Sources: OpenAlex.

Their work

Papers
40 (first author 9, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
92
Papers, trials and grants by year

2015: 3 papers · 2016: 4 papers · 2017: 6 papers · 2018: 4 papers · 2019: 7 papers · 2020: 7 papers · 2021: 4 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 3 papers

Papers 40

  1. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … First author DOI 10.1002/jhbp.12181↗
  2. Clinical significance of intraductal papillary mucinous neoplasms incidentally detected in patients with extrapancreatic gastrointestinal malignancies with a f… First author DOI 10.1016/j.surg.2024.09.044↗
  3. Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. First author DOI 10.21873/anticanres.17792↗
  4. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… First author DOI 10.1245/s10434-022-12566-1↗
  5. ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement. First author DOI 10.1245/s10434-022-12584-z↗
  6. Minimally invasive surgery for pancreatic cancer. Co-author DOI 10.1007/s00595-020-02120-5↗
  7. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2021.04.013↗
  8. Laparoscopic distal pancreatectomy for intraductal papillary mucinous neoplasm-associated pancreatic cancer: A case report. First author DOI 10.1016/j.ijscr.2021.106376↗
  9. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Mult… Co-author DOI 10.29337/ijsp.142↗
  10. Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced-stage cancer? Co-author DOI 10.1002/ags3.12340↗
  11. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neopla… First author DOI 10.1007/s00428-020-02844-2↗
  12. High-risk lesions in the remnant pancreas: fate of the remnant pancreas after pancreatic resection for pancreatic cancer and intraductal papillary mucinous neo… Co-author DOI 10.1007/s00595-019-01852-3↗
  13. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in… First author DOI 10.1097/sla.0000000000003060↗
  14. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Co-author DOI 10.1371/journal.pone.0228015↗
  15. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. Co-author DOI 10.3892/ijo.2019.4951↗
  16. FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients. Co-author DOI 10.7150/jca.38399↗
  17. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  18. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Co-author DOI 10.1007/s00432-019-02860-z↗
  19. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Co-author DOI 10.1016/j.canlet.2018.12.005↗
  20. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07269-z↗
  21. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Co-author DOI 10.1245/s10434-019-07309-8↗
  22. ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcome… Co-author DOI 10.1245/s10434-019-07857-z↗
  23. S100P regulates the collective invasion of pancreatic cancer cells into the lymphatic endothelial monolayer. Co-author DOI 10.3892/ijo.2019.4812↗
  24. Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. Co-author DOI 10.1016/j.canlet.2017.10.010↗
  25. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2018.03.031↗
  26. Surveillance of patients with intraductal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant pa… Co-author DOI 10.1016/j.surg.2017.09.040↗
  27. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6761-6↗
  28. Autophagy inhibition enhances antiproliferative effect of salinomycin in pancreatic cancer cells. Co-author DOI 10.1016/j.pan.2017.08.009↗
  29. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.10.035↗
  30. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mi… Co-author DOI 10.1053/j.gastro.2017.01.010↗
  31. Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancr… Co-author DOI 10.18632/oncotarget.15430↗
  32. Cancer-associated peritoneal mesothelial cells lead the formation of pancreatic cancer peritoneal dissemination. Co-author DOI 10.3892/ijo.2016.3829↗
  33. Degree of desmoplasia in metastatic lymph node lesions is associated with lesion size and poor prognosis in pancreatic cancer patients. Co-author DOI 10.3892/ol.2017.6549↗
  34. Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sid… Co-author DOI 10.1007/s00268-016-3526-x↗
  35. Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. Co-author DOI 10.1016/j.canlet.2016.01.016↗
  36. Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. First author DOI 10.1111/cas.13024↗
  37. Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL. Co-author DOI 10.3892/ijo.2016.3389↗
  38. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000258↗
  39. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. Co-author DOI 10.1097/mpa.0000000000000393↗
  40. TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells. Co-author DOI 10.3892/ijo.2015.3022↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takao Ohtsuka · 34 shared papers, 2015–2025 · strength 3.04
  2. Masafumi Nakamura · 22 shared papers, 2016–2025 · strength 2.12
  3. Kohei Nakata · 22 shared papers, 2017–2025 · strength 1.99
  4. Yoshinao Oda · 22 shared papers, 2015–2025 · strength 1.75
  5. Kenoki Ohuchida · 22 shared papers, 2015–2021 · strength 1.49
  6. Masafumi Nakamura · 13 shared papers, 2016–2023 · strength 1.37
  7. Toshiya Abe · 14 shared papers, 2016–2025 · strength 1.01
  8. Yasuhisa Mori · 8 shared papers, 2017–2025 · strength 0.86
  9. Takashi Okumura · 13 shared papers, 2016–2021 · strength 0.83
  10. Shin Takesue · 10 shared papers, 2017–2020 · strength 0.69
  11. Chika Iwamoto · 9 shared papers, 2017–2021 · strength 0.67
  12. Kazuhiro Koikawa · 10 shared papers, 2017–2021 · strength 0.65
  13. Ryota Matsuda · 6 shared papers, 2019–2020 · strength 0.63
  14. Yohei Ando · 8 shared papers, 2017–2021 · strength 0.61
  15. Sho Endo · 10 shared papers, 2017–2019 · strength 0.60
  16. Hiromichi Nakayama · 9 shared papers, 2017–2020 · strength 0.60
  17. Shin Kibe · 8 shared papers, 2017–2020 · strength 0.59
  18. Koji Shindo · 7 shared papers, 2015–2021 · strength 0.58
  19. Masato Watanabe · 3 shared papers, 2020–2025 · strength 0.53
  20. Naoki Ikenaga · 3 shared papers, 2021–2023 · strength 0.52
  21. Makoto Hashizume · 7 shared papers, 2017–2020 · strength 0.45
  22. Hiroaki Nagano · 3 shared papers, 2021–2025 · strength 0.43
  23. Ryuichiro Kimura · 3 shared papers, 2019–2025 · strength 0.43
  24. Hiroki Kaida · 2 shared papers, 2021–2025 · strength 0.42
  25. Kiyoshi Saeki · 4 shared papers, 2019–2020 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.